Health AI Central
Peer-Reviewed Publication
Cancer2026;132(19):e70630.October 1, 2026Journal Article

Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials.

Le Su1, Mehmet Burcu1, Kayleen Ports2, Vlad Gradinariu2, Yahav Itzkovich2, Rahul Jain2, Karin Yamada1, Cumhur Tekin1, Lei Chen1
1Merck & Co., Inc., Rahway, New Jersey, USA.
2Medidata Solutions, Inc., A Dassault Systèmes Company, New York, New York, USA.
PubMed DOI

Abstract

BACKGROUND: Progression-free survival (PFS) is a common primary endpoint in first-line epithelial ovarian cancer (EOC) trials; however, its relationship with overall survival (OS) remains uncertain. The patient-level PFS-OS association among individuals with BRCA wild-type advanced EOC treated with first-line platinum-based chemotherapy was evaluated. METHODS: This retrospective analysis pooled p…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.